Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 22 Jun 2021 |

Image: X-Ray Blood Irradiator RS 3400 (Photo courtesy of Rad Source Technologies)
Rad Source Technologies (Buford, GA, USA), a supplier of commercial X-ray radiation products designed to replace self-shielded gamma irradiators, highlighted its newly redesigned RS 3400 Blood Irradiator at MEDLAB Middle East 2021.
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Latest MEDLAB 2021 News
- Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read more
New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, marked by poor survival rates and limited treatment options, especially in patients who do not respond to standard therapies.... Read moreHematology
view channel
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








